Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1

Main Article Content

Wendy Cantrell
Patricia Lee
Alan M Mendelsohn
Jeff Parno
Stephen J Rozzo
Wilson Liao


Psoriasis, Tildrakizumab, Biologics, Safety, Efficacy


Abstract not available.


1. Reich K, et al. Lancet. 2017;390:276–88.

2. Blauvelt A, et al. Br J Dermatol. 2018;179:615–22.

Most read articles by the same author(s)